Shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $32.00.
A number of research firms have weighed in on ODTX. Zacks Research raised Odyssey Therapeutics to a “hold” rating in a research note on Wednesday, June 3rd. Wall Street Zen cut shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 20th. Wedbush assumed coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set an “overweight” rating on the stock. Finally, JPMorgan Chase & Co. started coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “overweight” rating and a $26.00 price target on the stock.
Check Out Our Latest Analysis on ODTX
Odyssey Therapeutics Trading Up 3.6%
Odyssey Therapeutics (NASDAQ:ODTX – Get Free Report) last released its earnings results on Wednesday, June 17th. The company reported ($6.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($5.46).
Insider Activity at Odyssey Therapeutics
In other Odyssey Therapeutics news, Director Nan (Ln) Li purchased 1,111,111 shares of Odyssey Therapeutics stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the completion of the transaction, the director owned 3,333,516 shares of the company’s stock, valued at $60,003,288. This trade represents a 50.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dimension Capital Ii, L.P. purchased 1,111,111 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was acquired at an average cost of $18.00 per share, with a total value of $19,999,998.00. Following the transaction, the director directly owned 3,333,516 shares in the company, valued at $60,003,288. This trade represents a 50.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 4,183,777 shares of company stock valued at $75,319,986 over the last ninety days.
Featured Articles
- Five stocks we like better than Odyssey Therapeutics
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for Odyssey Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odyssey Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
